Clinical Trial Update: A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China [Phase 3]

View source ↗

Summary

Pfizer completed a Phase 3 trial evaluating the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infection | Phase 3 | Status: COMPLETED